Regeneron Pharmaceuticals, Inc. has many moving parts to prioritize this year as it transitions patients to a new version of its blockbuster ophthalmology drug Eylea (aflibercept), expands the use of Dupixent (dupilumab) to a potentially big new indication in chronic obstructive pulmonary disease (COPD), and advances an interesting pipeline that includes therapies for obesity, cancer, allergy and hearing loss.
CEO Leonard Schleifer cautioned investors during a first quarter sales and earnings call on 2 May that a US Food and Drug Administration approval of Dupixent, which it commercializes with Sanofi, in COPD could be delayed after the agency requested additional efficacy analyses on subpopulations from the two pivotal Phase III trials, BOREAS and NOTUS, which demonstrated Dupixent reduced exacerbations in patients
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?